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Abstract
Background: Studies suggest that micronutrients may modify the risk or delay progression of prostate cancer; however, the
molecular mechanisms involved are poorly understood. We examined the effects of lycopene and fish oil on prostate gene
expression in a double-blind placebo-controlled randomized clinical trial.
Methods: Eighty-four men with low risk prostate cancer were stratified based on self-reported dietary consumption of fish
and tomatoes and then randomly assigned to a 3-month intervention of lycopene (n = 29) or fish oil (n = 27)
supplementation or placebo (n = 28). Gene expression in morphologically normal prostate tissue was studied at baseline
and at 3 months via cDNA microarray analysis. Differential gene expression and pathway analyses were performed to
identify genes and pathways modulated by these micronutrients.
Results: Global gene expression analysis revealed no significant individual genes that were associated with high intake of
fish or tomato at baseline or after 3 months of supplementation with lycopene or fish oil. However, exploratory pathway
analyses of rank-ordered genes (based on p-values not corrected for multiple comparisons) revealed the modulation of
androgen and estrogen metabolism in men who routinely consumed more fish (p = 0.029) and tomato (p = 0.008) compared
to men who ate less. In addition, modulation of arachidonic acid metabolism (p = 0.01) was observed after 3 months of fish
oil supplementation compared with the placebo group; and modulation of nuclear factor (erythroid derived-2) factor 2 or
Nrf2-mediated oxidative stress response for either supplement versus placebo (fish oil: p = 0.01, lycopene: p = 0.001).
Conclusions: We did not detect significant individual genes associated with dietary intake and supplementation of
lycopene and fish oil. However, exploratory analyses revealed candidate in vivo pathways that may be modulated by these
micronutrients.
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Introduction
Many men with indolent prostate cancer detected by prostate-
specific antigen (PSA) screening will not exhibit disease progres-
sion during their lifetime. As such, their treatment and associated
side effects may be unnecessary [1]. Active surveillance is a
management strategy that offers close monitoring of localized
cancers to avoid or delay the comorbidity of invasive treatments
such as surgery or radiation [2]. Therapeutic intervention is
offered at early signs of disease progression. Recently, the
investigation of dietary and lifestyle interventions and other
chemoprevention strategies in the setting of active surveillance
has gained considerable acceptance [3]. For example, our group
recently reported the results of a pilot project involving 30 men
who underwent a three month intervention of a low-fat vegan diet
and comprehensive changes in lifestyle [4]. Expression profiling
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and pathway analysis identified significant down regulation of
genes involved in biological processes that have critical roles in
tumorigenesis.
Laboratory and animal experiments provide evidence that fish
oil [5] and lycopene [6] may play a protective role in prostate
cancer development. In addition, epidemiological studies have
shown that diets rich in fish and tomatoes, which are major
sources of dietary omega-3 fatty acids and lycopene, respectively,
are associated with a lower incidence of prostate cancer
[7,8,9,10,11]. We (Chan JM) [12] previously reported that greater
intakes of fish and tomato sauce after diagnosis of prostate cancer
were associated with a reduction in risk of prostate cancer
recurrence or progression in a cohort of 1202 prostate cancer
survivors. While these studies link lycopene and fish oil with
reduced prostate cancer progression risk, the molecular mecha-
nisms of action of these dietary factors have yet to be elucidated.
To understand the effects of lycopene and fish oil on prostate
gene expression, we conducted a randomized, double-blinded,
placebo-controlled clinical trial among men with newly diagnosed,
favorable-risk prostate cancer (MENS or Molecular Effects of
Nutrition Supplements). Eligible men were randomized to take
placebo, lycopene or fish oil supplements for three months. The
trial’s original hypotheses focused on quantitative RT-PCR
analysis of a priori genes of interest (IGF-1, IGF-1R, COX-2). The
results of this analysis were primarily null and have been reported
separately [13]. We now report on the a priori secondary outcomes
of global gene expression and pathway analyses of morphologically
normal prostate tissue before and after the intervention.
Methods
Study Design
The study design and rationale for MENS has been reported
previously [13]. The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1. Briefly, MENS was a three arm
randomized, double blinded placebo-controlled 90 day clinical
trial of fish oil and lycopene supplements with each compared to a
placebo. The interventions consisted of two 15 mg lycopene softgel
capsules daily (Lyc-O-MatoH donated by, Lycored, Israel) or three
1 gm fish oil capsules daily (that included 1098 mg eicosapentae-
noic (EPA) and 549 mg docosahexaenoic (DHA) fatty acids;
manufactured by Perfect Source, Fullerton, CA with active
ingredient donated by Roche Vitamins, Parsippany, NJ). The
placebo was provided by the respective manufacturers of the active
pills for lycopene and fish oil. All men were also given a standard
multivitamin (1 tablet/day, Dixon/Akyma) and instructed to
refrain from any other types of vitamin or mineral supplements
during the three months of intervention. The fish oil and lycopene
doses were selected based on the minimal and maximal range at
which previous clinical trials had observed physiologic effects and
no toxicity for lycopene [14,15,16,17,18] [19] [7,20] and fish oil
supplementation [21,22,23,24,25,26,27]. The intervention dura-
tion of three months was chosen based on previous studies that
reported on gene expression changes within three months
[15,21,28]; and based on consultation with local prostate cancer
advocates and support groups who advised that most men would
prefer not to stop other supplements for more than three-months.
Baseline dietary data on fish and tomato consumption was used
for stratification (i.e., more than 4 servings/day tomato product-
s = high; more than 2 servings/week fish = high; cut points based
on the published literature [12]) with patients randomized from
within each stratum to control for possible confounding when
comparing the intervention arms. The randomization sequence
for the 4 nutrition strata was generated using nQuery Advisor with
a block size of 9. For each stratum a sequence of randomized
assignments was generated and given to the research pharmacist.
When a patient was eligible for the study, the study coordinator
contacted the research pharmacist to determine the study arm
assignment; the research pharmacist then supplied the supple-
ments (or placebo) to the patient. V.W (study biostatistician)
generated the random allocation sequence, P.R.C. and other
participating urologist investigators at the University of California
San Francisco (UCSF) enrolled the participants. All participants,
study coordinators, and investigators except V.W. were blinded as
to the intervention assignment.
Study Population and Eligibility Criteria
Detailed inclusion and exclusion criteria were previously
reported [13]. Briefly, this study was conducted among men with
low burden prostate cancer who met the following criteria:
histologically documented prostate adenocarcinoma; extended
pattern biopsy within two years of study enrollment with a
Gleason sum 6 or lower and no pattern 4 or 5; no more than 33%
of biopsy cores positive for cancer; and no more than 50% of the
length of a tumor core involved by carcinoma; three serum PSA
levels performed at least 2 weeks apart over the past year prior to
randomization and all PSA levels ,=10 ng/ml. Target accrual
for this study was 97 men. The sample size was based upon the
primary study aim using Fisher’s exact test with a power of 81% to
investigate the difference in proportions of the change in 3 months
in specific genes between each supplement and the placebo arm.
All men provided verbal and written consent for participation, and
this study was approved in April 2003 by the UCSF Human
Research Protection Program, which is UCSF’s Institutional
Review Board.
Study outcomes
The primary outcome of the trial was limited to change in 2
specific genes (IGF-1 and COX-2) and has been reported previously
[13]. The current report provides results for the secondary,
exploratory aim, that was to investigate the changes in global gene
expression and modulation of canonical pathways in normal
prostate tissue between baseline and 3 month biopsies, and
between diet groups at baseline (see below).
Biopsy Processing
To procure fresh tissue for gene expression analysis, four 18-
gauge core needle core biopsy samples were collected from each
participant at baseline and at the three month follow-up (end of
intervention).
RNA Amplification and Microarray Analysis
Details of the RNA amplification and microarray analysis have
been previously described [4,29]. All data are MIAME compliant,
and the raw data has been deposited in to GEO under super-series
accession #GSE27140.
Array quality, removal of print run bias and differential
expression analysis
To identify differentially expressed genes between treatment
arms at baseline, a linear model was fit for each gene expressed as
the log2 ratio as the response variable and treatment arm the
independent variable, for arm pairs. Diet conditions were
dichotomized (high versus low for fish or tomato consumption)
to test the relationship between diet with gene expression at
baseline. To compare the effect after 3 months between each
Lycopene, Fish Oil, and Prostate Cancer
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supplement and the placebo, the difference in the log2 ratios for
each gene between the two time points (baseline and month 3) was
used as the response variable. The probability values were adjusted
by controlling the false discovery rate [30]. A change in gene
expression was identified as significant if the false discovery rate
was less than 0.05, meaning that fewer than 5% of false findings
would be expected among the genes declared to be differentially
expressed. The number of tests (multiple comparisons) performed
was 39,347, equal to the number of cDNA probes in the
microarray. All linear models were fit using the limma package
[31,32] in Bioconductor.
Canonical Pathway Analysis
A table containing 39,347 cDNA probes and their correspond-
ing Genbank accession ID and expression values (fold change and
unadjusted p-value) were uploaded into Ingenuity Pathways
Analysis (IPA) software (Ingenuity Systems, Redwood City, CA).
IPA was able to map 20,490 Genbank accession IDs to genes (or
molecules) present in its database. IPA then assigned gene
ontology descriptions of biological function and generated
networks of gene interactions on the basis of information retrieved
from the software’s literature database. Genes that met the cut-off
(discussed in the results section) were included in the pathway
analysis. Canonical pathways analysis identified the significant
pathways from the Ingenuity Pathways Analysis library of
canonical pathways that reflected the gene expression in this
dataset. Fisher’s exact test was used to calculate a probability value
that indicated the association between each gene in the dataset
and the canonical pathway. A probability value #0.05 was chosen
to indicate a statistically significant over-representation of
molecules in our experiment compared with a curated pathway.
Results
Patient characteristics
We enrolled 97 men (target accrual) between October 2003 and
December 2007. Baseline clinical and demographic data of the
patient cohort were previously described in detail [13]. Thirteen
(13) participants were excluded due to ineligibility (n = 5),
voluntary withdrawal (n = 3), disease progression (n= 4), or
protocol violation (n= 1). The remaining 84 participants com-
prised the study sample for analysis.
Tumor tissue yield
Four core biopsies were collected from each of the 84 patients at
baseline and at 3 months. Two of the four cores for each patient
were obtained from area(s) containing tumor as previously
diagnosed and the remaining two were obtained from area(s) with
no involvement. Of all the 168 biopsies taken from regions with
tumor involvement, only 20% contained tumor, i.e. 35 (20.8%)
baseline biopsy cores from 26 patients and 30 (17.9%) 3-month
biopsy cores from 23 patients. As expected, the tumor yield was
low given initial patient eligibility criteria. Per our prior
hypotheses, the gene expression analyses focused on microarray
data from morphologically normal prostate tissue samples for all
84 patients.
Microarray data and quality assessment
A standardized qualitative assessment of array quality was
performed using the Bioconductor arrayQuality package [33].
Because a patient may have samples on 2 to 4 arrays at both
baseline and 3 months, an array with the best quality measures for
each time point was chosen. A total of 84 pairs representing a
baseline and three month gene expression data from each patient
were subjected to global normalization and differential expression
analysis.
Since the cDNA microarrays were printed in 7 batches over 3
years, the effect of print batch was explored. Unsupervised
hierarchical clustering revealed that samples hybridized to
microarrays from the same print batch clustered together. An
attempt to remove the print batch residual (see Methods S1) was
not completely successful, although a considerable improvement
was observed (Figure S1). Of note, samples did not cluster based
on treatment arms or time point (data not shown).
To verify the quality of the microarray data, we compared the
baseline gene expression from morphologically normal tissue with
available matched tumor tissue from 10 patients. Differential
expression analysis revealed genes that have been previously
reported to be up regulated in prostate cancer, e.g. HPN [34] and
AMACR [35] (data not shown).
To determine comparability of study arms, baseline gene
expression profiles for supplementation groups, lycopene (n= 29)
and fish oil (n = 27), were each compared to the placebo group
(n= 28). Differentially expressed genes were not detected,
suggesting that baseline gene expression across all intervention
and placebo groups were not significantly different. As reported
previously, baseline demographic and clinical characteristics were
also similar across treatment arms [13].
Fish and tomato consumption: baseline gene expression
and pathway analysis
Prior to randomization, patients were stratified based on self-
reported fish and tomato consumption (i.e., high fish (n = 26), low
fish (n = 58); and high tomato (n= 49) and low tomato (n= 35)).
Comparison of baseline gene expression profiles between different
nutrient groups revealed no differentially expressed genes after
adjustment for multiple comparisons.
Because no individual gene met the threshold for statistical
significance (adjusted p-value ,0.05), we explored potential
biological information contained in lists of genes that showed the
largest difference between groups being compared [36]. In this
study, we chose the unadjusted p-value (not corrected for multiple
comparisons) as a means to rank the genes from top to bottom i.e.,
those at the top are the most differentially expressed genes between
two groups. We then used the threshold (unadjusted p-value
#0.05) to select the top genes to be included in the pathway
analysis. For example, applying the threshold to the rank-ordered
genes associated with self-reported high dietary consumption of
tomato or fish yielded 482 and 192 top genes, respectively (Tables
S1 and S2). Each of these lists of genes was then separately used as
the input for pathway analysis via IPA. Results of the canonical
pathway analysis revealed several interesting pathways that may
be associated with high dietary consumption of tomato or fish
(Tables 1 and 2). For example, docosahexaenoic acid (DHA) and
insulin receptor signaling were modulated among men with high
fish consumption versus men who consumed less fish. High tomato
consumption revealed the modulation of genes involved in
selenoamino acid metabolism. Furthermore, androgen and
estrogen metabolism were both modulated among men who
routinely ate more fish and tomatoes versus men who consumed
less.
Lycopene or fish oil supplementation: gene expression
and pathway analysis
To investigate the effect of lycopene or fish oil supplementation
on the prostate, the change in expression from men who took
lycopene or fish oil supplements were compared to men in the
Lycopene, Fish Oil, and Prostate Cancer
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placebo group. After correcting for multiple testing, no individual
gene met the threshold for statistical significance (adjusted p-value
#0.05).
Similar to the approach described above, we applied the cut-off
(unadjusted p-value #0.05) to the rank-ordered genes associated
with lycopene or fish oil supplementation. To increase the
stringency of the analysis, we only included genes that had $1.5
fold change compared to the placebo. Using these thresholds, 57
and 80 genes (Tables S3 and S4) for lycopene and fish oil,
respectively, were included for pathway analysis. Results of the
canonical pathway analysis revealed the modulation of the
arachidonic acid metabolism in the fish oil arm (p= 0.01)
compared to placebo; while Nrf2-mediated oxidative response
was observed in both supplement arms when each was compared
to placebo (p= 0.01, fish oil; p = 0.001, lycopene; Table 3 and 4).
Discussion
The MENS (Molecular Effects of Nutritional Supplements)
study was a double-blinded placebo-controlled randomized
clinical trial that was developed based on the epidemiological
and clinical evidence that linked lycopene and fish oil with reduced
prostate cancer incidence and progression [10,11,12]. This trial
demonstrated the feasibility and safety of studying the effects of
nutritional supplements on prostate gene expression in men with
low-risk prostate cancer opting for active surveillance. In addition,
this study provided further evidence that active surveillance can
offer a unique window of opportunity for investigating potential
chemopreventive agents [37,38]. Other trials including the Men’s
Eating and Living Study (MEAL) also provide important data on
the feasibility of implementing clinical trials of dietary intervention
in men with low risk prostate cancer [4,15,39,40,41].
We examined the relationship between baseline gene expression
patterns and self-reported dietary intake levels of fish and tomato,
and studied the effects of short-term lycopene or fish oil
supplementation on the change in prostate gene expression.
Taking into account the adjustment for multiple comparisons
required in microarray analysis, both analyses yielded no
individual gene that was differentially expressed. These results
suggest that there were no differences between the groups
compared, or that changes in expression were too subtle to be
detected given a threshold. Modest alterations in gene expression
are difficult to distinguish from noise especially when there is a
large number of genes tested, limited samples and high variability
between individuals [42]. In addition, potential changes in gene
expression may have been dampened by a combination of
biological and technical factors including: 1) the dosage and
formulation of lycopene and fish oil administered in our study did
not have the potency to cause changes in gene expression; 2) the
intervention period of three months may have been too short; 3)
Table 1. Pathway analysis of gene expression in
morphologically normal prostate tissue in men who have high
dietary intake of tomato (n = 49) compared with low dietary
tomato intake (n = 35).
Ingenuity Canonical Pathways p-value
Selenoamino Acid Metabolism 0.0029
Hepatic Cholestasis 0.0048
Oxidative Phosphorylation 0.0052
Ubiquinone Biosynthesis 0.0055
Androgen and Estrogen Metabolism 0.0079
Stilbene, Coumarine and Lignin Biosynthesis 0.0098
Methionine Metabolism 0.0105
Methane Metabolism 0.0135
CD27 Signaling in Lymphocytes 0.0339
doi:10.1371/journal.pone.0024004.t001
Table 2. Pathway analysis of gene expression in
morphologically normal prostate tissue in men who have high
dietary intake of fish (n = 26) compared with low dietary fish
intake (n = 58).
Ingenuity Canonical Pathways p-value
Aminoacyl-tRNA Biosynthesis 0.00001
Biosynthesis of Steroids 0.0001
Glycosaminoglycan Degradation 0.0017
Tryptophan Metabolism 0.0028
Nrf2-mediated Oxidative Stress Response 0.0069
Sphingolipid Metabolism 0.0079
Galactose Metabolism 0.0081
Pantothenate and CoA Biosynthesis 0.0091
Endoplasmic Reticulum Stress Pathway 0.0191
Inositol Metabolism 0.0219
Docosahexaenoic Acid (DHA) Signaling 0.0219
Hepatic Cholestasis 0.0269
C21-Steroid Hormone Metabolism 0.0275
Butanoate Metabolism 0.0275
Androgen and Estrogen Metabolism 0.0288
Stilbene, Coumarine and Lignin Biosynthesis 0.0302
Glycosphingolipid Biosynthesis - Ganglioseries 0.0372
Insulin Receptor Signaling 0.0380
Caveolar-mediated Endocytosis 0.0389
Sonic Hedgehog Signaling 0.0407
Cell Cycle: G1/S Checkpoint Regulation 0.0417
N-Glycan Biosynthesis 0.0417
N-Glycan Degradation 0.0447
doi:10.1371/journal.pone.0024004.t002
Table 3. Pathway analysis of gene expression in
morphologically normal prostate tissue in men who took
lycopene supplements for three months (n = 29) compared
with placebo (n = 28).
Ingenuity Canonical Pathways p-value
Nrf2-mediated Oxidative Stress Response 0.0014
Apoptosis Signaling 0.0072
Ceramide Signaling 0.0089
LPS/IL-1 Mediated Inhibition of RXR Function 0.0098
Glutamate Metabolism 0.0178
Axonal Guidance Signaling 0.0380
Glutathione Metabolism 0.0389
PXR/RXR Activation 0.0479
doi:10.1371/journal.pone.0024004.t003
Lycopene, Fish Oil, and Prostate Cancer
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variability due to diverse participants’ diets; 4) detectable changes
in gene expression may have occurred in tumors but were not
available for analysis; 5) the sample size was relatively small and 6)
the noise inherent to the cDNA microarray technology (e.g. print
batch effect) may have masked the relatively subtle effects on gene
expression.
Although no individual gene was significantly identified with
either baseline intake levels or change with lycopene or fish oil
supplement, we further explored our prostate gene expression data
for potential biological clues by performing pathway analyses of
genes (not adjusted for multiple comparisons) that showed the
largest differences between groups compared [36]. The unadjusted
p-value calculated for each gene was used to order and select top
ranking genes for pathway analyses. Canonical pathway analyses
(in IPA) revealed candidate pathways that were associated with
high dietary intake of tomato or fish at baseline as well as subtle
gene expression changes after lycopene and fish oil supplementa-
tion. These analyses were done to identify potential genes for
future study e.g., RT-PCR of selected genes in candidate pathways
modulated by dietary or supplementation of these micronutrients.
We observed that high dietary intake of fish modulated genes
involved in metabolic pathways including C21-steroid hormone
metabolism and insulin receptor signaling in the normal prostate
tissue. To the best of our knowledge, associations between fish
intake and steroid hormone metabolism or insulin receptor
signaling in the prostate have not been reported. However, the
modulation of docosahexaenoic acid (DHA) signaling makes sense
as DHA is a major component of fish oil. Studies have shown that
DHA inhibits growth of prostate cancer cells [43] and may
enhance the efficacy of taxanes, and possibly other drugs, such as
COX-2 inhibitors [44,45]. Moreover, we observed that fish oil
supplementation modulated genes involved in arachidonic acid
metabolism. In vivo and in vitro experimental studies have suggested
that arachidonic acid, an omega-6 fatty acid, plays a role in the
stimulation of proliferation genes that may lead to prostate cancer
[46]. Lowering omega-6:omega-3 fatty acid ratio by increased
intake of foods rich in omega-3 fatty acids (such as fish) and
perhaps by fish oil supplementation may have inhibitory effects on
prostate cancer as demonstrated in cell lines and xenografts
[5,12,21,46,47,48].
Selenoamino acid metabolism pathway was modulated in men
who had high tomato consumption. Selenoamino acids are
hypothesized to be responsible for the anti-cancer properties of
selenium compounds [49]. For example, seleno-methionine
selectively induced growth inhibition and apoptosis in prostate
cancer cells but not in normal cells [50], consistent with some of
the observational epidemiological data suggesting that selenium
may prevent prostate cancer. Of note, selenium supplementation
was not associated with reduction in incidence of prostate cancer
in the Selenium and Vitamin E Cancer Prevention Trial
(SELECT) [51]. We also observed that lycopene supplementation
modulated signaling pathways including apoptosis and ceramide
signaling. Ceramide is a family of lipid molecules that promote
apoptosis and cell cycle arrest [52]. Direct associations between
lycopene and ceramide signaling have not been reported,
however, lycopene’s apoptotic effects have been documented in
both xenografts and cancer cell lines [53,54,55]. Interestingly,
modulation of androgen and estrogen metabolism was observed in
men with high consumption of fish and tomatoes. Many dietary
factors, including a high omega-3 fatty acid diet, have been
documented to impact androgen or estrogen levels [56].
The Nrf2-mediated oxidative stress response pathway was
observed to be modulated by both lycopene and fish oil
supplement vs. placebo. Studies in mice have shown that the loss
of Nrf2 function correlated with increased reactive oxygen species
and DNA damage leading to the transformation of normal
prostate tissue [57]. In addition, a study in knock out mice
revealed a link between the chemopreventive effects of soy
isoflavones and the role of Nrf2 in modulating signaling pathways
involved in the prevention of prostate cancer [58]. Recent studies
have shown that other food-based or pharmacological compounds
also exert their chemopreventive effects via the Nfr2 signaling
pathway by mediating increased activity of cytoprotective
enzymes, e.g. phase II detoxifying and antioxidant enzymes
[59,60,61,62]. Taken together, the modulation of the Nrf2
signaling pathway may be an important molecular mechanism
involved in chemoprevention by several agents including lycopene
and fish oil. Interventions that target the Nrf2 pathway may offer a
promising strategy for chemoprevention.
Exploring the top genes (most differentially expressed) selected
after applying specified cut-offs revealed intriguing results. For
example, KLK3 (aka prostate specific antigen or PSA) was up
regulated in the lycopene arm (6.2 fold change) compared to the
placebo group (Table S3) while KLK3 was down regulated (22.5
fold change) in men who had high fish consumption at baseline
compared to men who consumed less fish (Table S2). Of note,
IGF1 was down regulated in the fish oil arm (21.5 fold change)
compared to the placebo group (Table S4). Down regulation of
IGF1 was not observed in the lycopene arm. While provocative,
care should be exercised when interpreting these results since these
genes were not significant after adjustment for multiple compar-
isons.
Except for Nrf2-mediated oxidative stress response, none of the
pathways identified after supplementation overlapped with the
pathways identified at baseline. Interestingly, there are on-going
debates [63] whether obtaining nutrients from whole food has the
same health impacts as supplementation. Besides lycopene and fish
oil (DHA/EPA), other naturally occurring nutrients in whole
tomatoes (e.g. other carotenoids) [64] and fish (e.g. alpha-linolenic
acid) may also be important to the positive health effects of these
foods. However, interpretations made from comparing the results
between the analysis of baseline and supplementation groups in
this study should be done with caution because the baseline and
intervention analyses were originally designed to measure different
outcomes.
Recent research in personalized nutrition has demonstrated that
nutrients may interact with an individual’s genotypic and
phenotypic background [65,66]. For example, supplements may
Table 4. Pathway analysis of gene expression in
morphologically normal prostate tissue in men who took fish
oil supplements for three months (n = 27) compared with
placebo (n = 28).
Ingenuity Canonical Pathways p-value
Nrf2-mediated Oxidative Stress Response 0.0123
Arachidonic Acid Metabolism 0.0135
Glutathione Metabolism 0.0204
Cyanoamino Acid Metabolism 0.0209
Metabolism of Xenobiotics by Cytochrome P450 0.0316
Alanine and Aspartate Metabolism 0.0324
GABA Receptor Signaling 0.0437
Nitrogen Metabolism 0.0457
doi:10.1371/journal.pone.0024004.t004
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24004
affect gene expression in different directions (i.e. up- or down
regulation) depending on the genotype/phenotype of the individ-
ual. Furthermore, nutrients may produce different phenotypes in
patients with different genotypes. A P450 cytochrome allele, for
instance, may metabolize a dietary substrate to a bioactive form, in
contrast to another allele that produces an inactive metabolite
[67]. Hence, variability among patients may cancel out the effects
of the dietary factors if analyzed at the global level resulting in an
undetectable net change. As more examples of diet-gene
interactions are discovered, increased power and sophistication
of clinical trials will become possible.
A more recent report from the Selenium and Vitamin E Cancer
Prevention Trial (SELECT) demonstrated the cell and tissue
specific effects of selenium and vitamin E on gene and protein
expression in the prostate [68]. They detected differentially
expressed genes (relative to the placebo group) in men who were
taking selenium or vitamin E or in combination, only when cell
type (normal epithelium, stroma or tumor) was taken into
consideration. In the MENS study, morphologically normal tissue
used for gene expression contained both stroma and normal
epithelium; hence, cell type specific analysis was not possible.
Although differential expression analysis did not detect
significant individual genes, our exploratory analysis revealed
candidate in vivo pathways that may be modulated by dietary fish
and tomato intakes or by lycopene and fish oil supplementation.
Our study provides a platform to investigate the bioactivity and
relevance of nutrients in prostate cancer. Understanding molec-
ular mechanisms by which micronutrients affect gene expression
would have a great impact on the development of prevention and
treatment strategies in prostate cancer, especially for men electing
active surveillance. Finally, improvements in commercial RNA
amplification, oligonucleotide microarray platforms, potency and
longer intervention periods are important factors to consider when
performing gene expression studies for agents that have subtle
effects on the human transcriptome.
Supporting Information
Figure S1 Samples were hybridized to 7 different batches of
printed cDNA microarrays (#11, 12, 14, 17, 18, 19 and 20). Print
run effect was controlled by fitting a linear model with log2 ratio as
response and batch effect as explanatory variable and using the
residuals from the fit for further analyses.
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